NMTRQ
9 Meters Biopharma, Inc.
OTC Markets OTCPKUSDEQUITY
DELAYED
Last price
0.00
■ 0.00 (0.00%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
—
Prev close
0.00
Day high
0.00
Day low
0.00
Volume
5.96K
Market cap
—
P/E (TTM)
—
52W range
— – 0.00
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
0.00%
+1.4%
1M
0.00%
-3.7%
3M
+900.00%
+896.9%
6M
-80.00%
-91.1%
YTD
0.00%
-12.3%
1Y
0.00%
-20.0%
3Y
-99.46%
-173.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2022 | 2021 | YoY |
|---|---|---|---|
| Total revenue | $0 | $0 | — |
| Operating revenue | $0 | $0 | — |
| Research & development | $31.01M | $22.00M | +41.0% |
| Selling, general & admin | $11.01M | $9.66M | +13.9% |
| Total operating expense | $42.02M | $31.66M | +32.7% |
| Operating income | -$42.02M | -$31.66M | -32.7% |
| Net interest income | -$2.17M | -$24.48K | -8,747.9% |
| Pre-tax income | -$43.77M | -$36.78M | -19.0% |
| Tax provision | $0 | $0 | — |
| Net income | -$43.77M | -$36.78M | -19.0% |
| Net income to common | -$43.77M | -$36.78M | -19.0% |
| Basic EPS | -3.38 | -3.03 | -11.6% |
| Diluted EPS | -3.38 | -3.03 | -11.6% |
| EBIT | -$41.10M | -$36.73M | -11.9% |
| EBITDA | -$41.09M | -$36.72M | -11.9% |
| Basic shares | 12.96M | 12.16M | +6.6% |
| Diluted shares | 12.96M | 12.16M | +6.6% |
| Line item | 2022 | 2021 | YoY |
|---|---|---|---|
| Cash & equivalents | $12.65M | $46.99M | -73.1% |
| Cash & short-term investments | $12.65M | $46.99M | -73.1% |
| Total current assets | $33.02M | $49.99M | -33.9% |
| Property, plant & equipment | $122.72K | $182.71K | -32.8% |
| Total assets | $33.15M | $50.17M | -33.9% |
| Total current liabilities | $30.70M | $8.46M | +263.0% |
| Current debt | $19.62M | — | — |
| Total debt | $19.73M | $167.94K | +11,648.1% |
| Total liabilities | $30.75M | $8.57M | +258.8% |
| Retained earnings | -$212.61M | -$168.84M | -25.9% |
| Shareholder equity | $2.40M | $41.60M | -94.2% |
| Working capital | $2.32M | $41.53M | -94.4% |
| Net tangible assets | $2.40M | $41.60M | -94.2% |
| Shares issued | 13.04M | 12.91M | +1.0% |
| Line item | 2022 | 2021 | YoY |
|---|---|---|---|
| Net income | -$43.77M | -$36.78M | -19.0% |
| Depreciation & amortisation | $8.52K | $7.57K | +12.5% |
| Stock-based compensation | $3.94M | $2.41M | +63.2% |
| Change in working capital | $661.42K | $2.23M | -70.4% |
| Operating cash flow | -$37.24M | -$29.48M | -26.3% |
| Capital expenditure | -$2.84K | -$2.51M | +99.9% |
| Investing cash flow | -$2.84K | -$2.43M | +99.9% |
| Financing cash flow | $19.91M | $41.05M | -51.5% |
| Free cash flow | -$37.25M | -$31.98M | -16.5% |
| End cash position | $29.66M | $46.99M | -36.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.00
+0.00% from price
SMA 20
0.00
0.00% from price
SMA 50
0.00
+60.77% from price
SMA 100
0.00
+177.01% from price
SMA 200
0.00
-9.75% from price
EMA 12
0.00
+0.71% from price
EMA 26
0.00
+10.53% from price
EMA 50
0.00
+30.44% from price
RSI (14)
98.1
Overbought
MACD (12,26,9)
0.00
Hist -0.00
ATR (14)
0.00
—
Realised vol 30D
656.1%
Annualised
Bollinger upper
0.00
20, 2σ
Bollinger lower
0.00
20, 2σ
50 / 200 cross
Death
0.00 vs 0.00
Trend bias
Below 200
-9.75%
Risk profile
Beta vs SPY
5.33
More volatile than market
Correlation to SPY
0.05
Largely independent
Realised vol 30D
656.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-98.0%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.00
Average true range
Beta (reported)
—
5Y monthly, from filing
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.